Kashi na hudu da aka fi sani da kansa a tsakanin mata a fadin duniya dangane da adadin sabbin masu kamuwa da cutar da mace-mace shi ne kansar mahaifa bayan nono, launin fata da huhu. Akwai hanyoyi guda biyu na guje wa kansar mahaifa - rigakafin farko da rigakafin sakandare. Rigakafin farko yana hana masu kamuwa da cutar sankara tun da fari ta amfani da allurar rigakafin HPV. Rigakafin na biyu yana gano raunukan da suka rigaya kafin kamuwa da cutar kansa ta hanyar tantance su da kuma yi musu magani kafin su koma kansa. Hanyoyi guda uku da aka saba aiwatarwa sun kasance don tantance cutar kansar mahaifa, kowanne an tsara shi don takamaiman yanayin zamantakewa da tattalin arziƙin viz VIA, gwajin smear cytology/Papanicolaou (Pap) da gwajin DNA na HPV. Ga yawancin mata, ƙa'idodin WHO na kwanan nan na 2021 yanzu suna ba da shawarar yin gwaji tare da HPV DNA azaman gwaji na farko da ya fara daga shekaru 30 a tsakanin shekaru biyar zuwa goma maimakon Pap Smear ko VIA. Gwajin DNA na HPV yana da mafi girman hankali (90 zuwa 100%) idan aka kwatanta da pap cytology da VIA. Hakanan yana da tsada fiye da dabarun duba gani ko cytology kuma ya dace da duk saituna.
Samfuran kai wani zaɓi ne wanda WHO ta ba da shawarar. musamman ga matan da ba su da kyau. Fa'idodin dubawa ta amfani da gwajin HPV da aka tattara da kansu sun haɗa da ƙarin dacewa da rage shinge ga mata. Inda ake samun gwajin HPV a matsayin wani ɓangare na shirin ƙasa, zaɓin samun damar yin samfurin kai na iya ƙarfafa mata su sami damar yin gwaje-gwaje da sabis na jiyya da kuma inganta ɗaukar hoto. Samfuran kai na iya taimakawa wajen cimma burin duniya na ɗaukar hoto na 70% na 2030. Mata na iya jin daɗin ɗaukar samfuran kansu, maimakon zuwa ganin ma'aikacin lafiya don auna cutar kansar mahaifa.
